StocksFundsScreenerSectorsWatchlists
RLAY

RLAY - Relay Therapeutics Inc Stock Price, Fair Value and News

8.30USD+0.14 (+1.72%)Market Closed

Market Summary

RLAY
USD8.30+0.14
Market Closed
1.72%

RLAY Alerts

  • Big fall in Revenue (Y/Y)
  • Losses in recent quarter

RLAY Stock Price

View Fullscreen

RLAY RSI Chart

RLAY Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-3.18

Price/Sales (Trailing)

24.09

Price/Free Cashflow

-3.58

RLAY Price/Sales (Trailing)

RLAY Profitability

Return on Equity

-45.47%

Return on Assets

-40.52%

Free Cashflow Yield

-27.96%

RLAY Fundamentals

RLAY Revenue

Revenue (TTM)

45.2M

Rev. Growth (Yr)

-28.21%

Rev. Growth (Qtr)

-78.18%

RLAY Earnings

Earnings (TTM)

-342.0M

Earnings Growth (Yr)

-23.69%

Earnings Growth (Qtr)

-27.02%

Breaking Down RLAY Revenue

Last 7 days

-2.0%

Last 30 days

-28.1%

Last 90 days

-30.7%

Trailing 12 Months

-48.1%

How does RLAY drawdown profile look like?

RLAY Financial Health

Current Ratio

25.44

RLAY Investor Care

Shares Dilution (1Y)

1.96%

Diluted EPS (TTM)

-2.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202321.6M34.5M47.4M45.2M
20222.0M2.1M5.5M8.8M
202162.2M41.7M21.3M830.0K
202007.2M5.3M82.7M
20190000

Tracking the Latest Insider Buys and Sells of Relay Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 29, 2024
catinazzo thomas
sold
-19,328
9.64
-2,005
chief financial officer
Jan 29, 2024
bergstrom donald a
sold
-30,635
9.64
-3,178
president, r&d
Jan 29, 2024
adams brian
sold
-18,595
9.64
-1,929
chief legal officer
Jan 29, 2024
rahmer peter
sold
-15,915
9.64
-1,651
see remarks
Jan 16, 2024
catinazzo thomas
acquired
-
-
200,000
chief financial officer
Jan 16, 2024
rahmer peter
acquired
-
-
200,000
see remarks
Jan 16, 2024
bergstrom donald a
acquired
-
-
300,000
president, r&d
Jan 16, 2024
patel sanjiv
acquired
-
-
762,360
president and ceo
Jan 16, 2024
adams brian
acquired
-
-
200,000
chief legal officer
Dec 27, 2023
catinazzo thomas
sold
-3,383
11.51
-294
chief financial officer

1–10 of 50

Which funds bought or sold RLAY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
506
506
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
sold off
-100
-824,180
-
-%
Mar 11, 2024
VANGUARD GROUP INC
added
0.93
28,515,400
117,261,000
-%
Mar 04, 2024
CONGRESS ASSET MANAGEMENT CO /MA
added
0.37
386,674
1,618,180
0.01%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
120
14,155,800
21,654,200
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
115,156
494,085
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
sold off
-100
-16,341,400
-
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
new
-
1,083,530
1,083,530
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-80.44
-702,000
241,000
0.02%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-0.32
22,077,000
94,480,000
0.01%

1–10 of 48

Are Funds Buying or Selling RLAY?

Are funds buying RLAY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RLAY
No. of Funds

Unveiling Relay Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
price t rowe associates inc /md/
7.0%
8,589,425
SC 13G
Feb 14, 2024
casdin capital, llc
5.99%
7,387,943
SC 13G/A
Feb 13, 2024
vanguard group inc
8.64%
10,650,387
SC 13G/A
Jan 26, 2024
blackrock inc.
7.8%
9,573,423
SC 13G/A
Jan 23, 2024
state street corp
3.98%
4,903,578
SC 13G/A
Oct 02, 2023
casdin capital, llc
5.16%
6,298,574
SC 13G
Jul 10, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.59%
10,384,218
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 03, 2023
state street corp
5.18%
6,264,497
SC 13G

Recent SEC filings of Relay Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 22, 2024
10-K
Annual Report
Feb 22, 2024
8-K
Current Report
Feb 22, 2024
S-8
Employee Benefits Plan
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading

Peers (Alternatives to Relay Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.7B
6.8B
19.31% -24.90%
-8.64
5.95
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.8B
1.8B
-0.33% -18.28%
-42.76
10.3
76.23% 61.08%
16.5B
2.4B
-4.10% -7.32%
98.3
6.81
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.4
3.46
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.41
17.87
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.32
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.8
13.97
440.80% -27.84%
3.5B
240.7M
-7.70% 7.49%
-11.94
14.72
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-49.71
4.19
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.31
4.72
85.90% -14.05%
669.0M
983.7M
12.98% -18.87%
-1.23
0.68
-50.36% 17.16%
411.7M
881.7K
51.26% 463.55%
-9.23
466.16
-77.61% -5.33%
324.4M
4.9M
46.53% -11.16%
-2.4
66.66
-54.97% 51.72%
14.1M
2.1M
-13.49% -43.81%
-0.52
2.14
-13.45% 66.37%

Relay Therapeutics Inc News

Latest updates
MarketBeat • 24 hours ago
Nasdaq • 18 Mar 2024 • 03:56 pm
Seeking Alpha • 13 Mar 2024 • 07:00 am

Relay Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q32019Q2
Revenue-78.2%5.0025.008.007.008.004.001.001.000.000.001.0040.0080.001.001.002.002.002.00
Operating Expenses-6.7%92.0099.0010610173.0086.0078.0063.0068.0062.0019443.0048.0037.0028.0026.0022.0020.00
  S&GA Expenses-9.3%17.0018.0020.0020.0016.0016.0017.0016.0016.0015.0014.0013.0016.0012.006.005.004.004.00
  R&D Expenses------------31.0032.0024.0022.0022.0018.0016.00
Net Income-27.0%-83.49-65.73-98.50-94.24-67.50-84.17-76.79-62.05-67.46-60.83-193-42.1835.00-36.08-26.72-24.89-19.67-17.54
Net Income Margin-9.9%-7.57*-6.88*-22.81*-37.77*-126.42*-64.39*-61.78*-92.18*-120.13*-11.39*-5.52*-1.11*------
Free Cashflow-17.5%-89.31-75.99-70.10-69.04-59.39-68.24-58.95-51.97-40.59-54.93-28.5246.00------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets-6.9%8449079621,0381,1001,1698899501,008672714771800752348393
  Current Assets-7.4%7708328849581,0201,087856916976639681742770722316361
    Cash Equivalents-5.0%14415114616115235510811928322926026344955913743.00
  Net PPE1.9%11.0011.0012.0012.0012.0011.009.009.007.006.007.006.006.007.007.008.00
Liabilities-28.5%92.0012915215415016911010811110196.0039.0037.0038.0036.0036.00
  Current Liabilities-40.4%30.0051.0072.0070.0064.0071.0044.0042.0024.0029.0025.0016.0014.0016.0013.0012.00
Shareholder's Equity-3.4%7527788108839501,000780842898571619733763714--
  Retained Earnings-6.3%-1,400-1,317-1,251-1,152-1,058-991-906-830-768-700-639-446-404-439-241-189
  Additional Paid-In Capital2.6%2,1532,0992,0672,0422,0192,0041,6981,6811,6671,2721,2581,1791,1671,15315.009.00
Shares Outstanding3.5%12712312212112111110910895.0093.0092.0090.00----
Float---1,500---1,800---2,264-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations-18.3%-89,188-75,397-68,601-67,130-57,079-66,145-57,093-49,173-39,707-53,199-28,14046,640-35,272-24,039-20,844-22,334---
  Share Based Compensation-11.8%19,26721,83523,41121,51813,81713,71915,14713,45510,21812,41816,1479,67114,54411,9294,0321,455-1,2481,086
Cashflow From Investing-16.4%59,67871,36551,27775,314-146,93627,18743,388-112,384-292,74520,78726,068-233,621-76,42020,07387,64850,371---
Cashflow From Financing131.7%21,9189,4582,0801,2971,166285,8651,996883384,0129021,1212,05556.00426,195-93.00351---

RLAY Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
License and other revenue$ 25,546$ 1,381$ 3,029
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]us-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMember
Total revenue$ 25,546$ 1,381$ 3,029
Operating expenses:   
Research and development expenses330,018246,355172,650
In-process research and development expenses  123,000
Loss on initial consolidation of variable interest entity  11,855
Change in fair value of contingent consideration liability(6,422)(11,677)2,836
General and administrative expenses74,95065,97857,386
Total operating expenses398,546300,656367,727
Loss from operations(373,000)(299,275)(364,698)
Other income:   
Interest income31,0458,786830
Other expense(18)(20)(4)
Total other income, net31,0278,766826
Net loss$ (341,973)$ (290,509)$ (363,872)
Net loss per share, basic$ (2.79)$ (2.59)$ (3.82)
Net loss per share, diluted$ (2.79)$ (2.59)$ (3.82)
Weighted average shares of common stock, basic122,576,527112,233,64995,136,719
Weighted average shares of common stock, diluted122,576,527112,233,64995,136,719
Other comprehensive loss:   
Unrealized holding gain (loss)$ 10,224$ (9,332)$ (1,152)
Total other comprehensive gain (loss)10,224(9,332)(1,152)
Total comprehensive loss$ (331,749)$ (299,841)$ (365,024)

RLAY Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 143,736$ 151,794
Investments606,350847,123
Accounts receivable 306
Contract asset 4,913
Prepaid expenses16,70212,110
Other current assets3,3153,259
Total current assets770,1031,019,505
Property and equipment, net10,90111,634
Operating lease assets57,96963,754
Restricted cash2,7072,578
Intangible asset2,3002,300
Total assets843,9801,099,771
Current liabilities:  
Accounts payable9,21110,578
Accrued expenses14,89022,703
Operating lease liabilities4,9644,276
Other current liabilities1,20426,152
Total current liabilities30,26963,709
Operating lease liabilities, net of current portion48,50253,466
Contingent consideration liability13,20632,378
Total liabilities91,977149,553
Commitments and contingencies (Note 12)
Stockholders' equity:  
Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2023, and December 31, 2022;127,462,409 and 121,112,234 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively127121
Additional paid-in capital2,152,6542,019,126
Accumulated other comprehensive loss(196)(10,420)
Accumulated deficit(1,400,582)(1,058,609)
Total stockholders' equity752,003950,218
Total liabilities and stockholders' equity$ 843,980$ 1,099,771
RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.relaytx.com
 EMPLOYEES345

Relay Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Relay Therapeutics Inc? What does RLAY stand for in stocks?

RLAY is the stock ticker symbol of Relay Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Relay Therapeutics Inc (RLAY)?

As of Wed Mar 27 2024, market cap of Relay Therapeutics Inc is 1.07 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RLAY stock?

You can check RLAY's fair value in chart for subscribers.

What is the fair value of RLAY stock?

You can check RLAY's fair value in chart for subscribers. The fair value of Relay Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Relay Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RLAY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Relay Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RLAY is over valued or under valued. Whether Relay Therapeutics Inc is cheap or expensive depends on the assumptions which impact Relay Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RLAY.

What is Relay Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, RLAY's PE ratio (Price to Earnings) is -3.13 and Price to Sales (PS) ratio is 23.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLAY PE ratio will change depending on the future growth rate expectations of investors.